Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Chilean Interventional Open Label Pilot Study, to Assess the Efficacy and Safety of Lucentis (Ranibizumab Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema.

Next Previous
Trial Profile

Chilean Interventional Open Label Pilot Study, to Assess the Efficacy and Safety of Lucentis (Ranibizumab Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Feb 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals

Most Recent Events

  • 02 May 2017 Status changed from active, no longer recruiting to completed.
  • 30 Jun 2016 Planned End Date changed from 1 Apr 2015 to 1 Jan 2017.
  • 30 Jun 2016 Planned primary completion date changed from 1 Apr 2015 to 1 Jan 2017.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top